Market Cap

CanBas Co. Ltd Market Capitalization:

¥16.51 Billion

JPY as of Jan. 1, 2026

US$105.4 Million

business CanBas Co. Ltd Company Profile

CanBas Co. Ltd Main Stock Listing

JPX: 4575

Market Capitalization History of CanBas Co. Ltd

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Top Competitors by Market Capitalization

Industry: Biotechnology
Company Market Cap (USD)
Novo Nordisk $158.96 B
Vertex Pharmaceuticals Incorporated $115.92 B
CSL Limited $95.75 B
Regeneron Pharmaceuticals, Inc. $82.28 B
Marinomed Biotech AG $70.11 B
Sector: Healthcare
Company Market Cap (USD)
Lilly $968.50 B
Johnson & Johnson $499.57 B
AbbVie $405.28 B
Roche $332.12 B
UnitedHealth Group $304.72 B

Yearly evolution of CanBas Co. Ltd market cap

Date Market Cap YoY Change
Jan. 1, 2026 ¥16.51 B 6.28%
Jan. 1, 2025 ¥15.54 B -10.19%
Jan. 1, 2024 ¥17.30 B -15.01%
Jan. 1, 2023 ¥20.35 B 382.50%
Jan. 1, 2022 ¥4.22 B -45.84%
Jan. 1, 2021 ¥7.79 B -44.41%
Jan. 1, 2020 ¥14.01 B 92.55%
Jan. 1, 2019 ¥7.28 B -36.36%
Jan. 1, 2018 ¥11.43 B 25.04%
Jan. 1, 2017 ¥9.14 B -20.13%
Jan. 1, 2016 ¥11.45 B -55.76%
Jan. 1, 2015 ¥25.88 B 111.32%
Jan. 1, 2014 ¥12.25 B 33.94%
Jan. 1, 2013 ¥9.14 B 16.73%
Jan. 1, 2012 ¥7.83 B -35.80%
Jan. 1, 2011 ¥12.20 B -49.69%
Jan. 1, 2010 ¥24.25 B

Market capitalization is calculated from the opening stock price at the beginning of each year.

⛩️ Moltgate
Spam is free. Your attention isn’t.
Turn your inbox into a paid channel. Set your price lanes $10 / $30 / $100 and only get messages worth reading.
Get Started Free
Built for busy humans + 🦞 AI agents. Plain-text only.

CanBas Co. Ltd Categories

Japan languages Healthcare languages Biotechnology
Japan Healthcare Japan Biotechnology

Stocks & Indices

CanBas Co. Ltd has the following listings and related stock indices.


Stock: JPX: 4575

What is a company's market capitalization?

The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.